Cardiovascular disease and cancer are leading contributors to the global disease burden. 5 fluorouracil (5-FU) is a commonly used drug in gastrointestinal cancers with known cardiotoxicity.

The proposed mechanisms underlying cardiotoxicity induced by 5-fluorouracil (5-FU) are vascular endothelial damage followed by thrombus formation, ischaemia secondary to coronary artery vasospasm, direct toxicity on myocardium and thrombogenicity.

Pharmacogenomic studies and genetic profiling may help predict the occurrence and streamline the treatment of 5-FU-induced coronary artery vasospasm.

This webinar focuses on the mechanisms of 5-FU cardiotoxicities and current management strategies. Future potential treatments will also be reviewed.